There has been a growing interest in stem cell therapy options in recent years. Notably, while therapies utilizing autologous stem cells are mainstream in Japan, the number of individuals seeking therapies with younger stem cells continues to rise.
However, undergoing therapy with allogeneic young stem cells necessitates selecting a medical facility abroad. Consequently, many individuals find it challenging to make an informed decision due to the limited availability of reliable information concerning the choice of country.
Therefore, this article discusses Southeast Asian countries providing stem cell therapy, with a particular focus on those requiring special safety considerations.
Proliferation of Illegal Clinics: Thailand
When you search for "Thailand stem cell," news articles with titles such as "A Growing Number of Foreigners Flock to the World's Only Country Where Stem Cell Therapy Is Possible" often appear prominently in search results.
However, many of these articles are based on information from 2007 and may not reflect the current situation. When researching information on stem cell therapy abroad using Japanese sources, the available information is often not up-to-date, making careful verification necessary.
Previously, serious incidents related to stem cell therapy occurred in Thailand, and the government subsequently prohibited stem cell therapy for diseases other than specific conditions (leukemia, multiple myeloma, congenital immunodeficiency, other blood cancers).
As a result, there are no unified safety standards concerning stem cell cultivation, and there have been reported cases involving the use of imported stem cells.
Additionally, regarding stem cell retrieval, donor eligibility is unclear, and in some areas, concerns exist about potential involvement in illegal organ trafficking.
Furthermore, excessive advertising for stem cell clinics in Thailand has become an issue, and according to a report dated October 31, 2024, over 400 lawsuits are reportedly filed annually (Source: Nation Thailand).
In Thailand, the provision of unlicensed stem cell therapy has become a significant concern. In 2024, the government is actively identifying uncertified stem cell clinics and issuing closure orders for facilities found to be engaging in illegal medical practices. According to the Thai Ministry of Public Health (MOPH), stem cell therapy is strictly limited to treating conditions such as leukemia, multiple myeloma, congenital immunodeficiency, and other blood cancers. Treatments offered for any other diseases may be deemed illegal.
Currently, stem cell therapy in Thailand is only recognized for the following conditions:
- Leukemia
- Multiple Myeloma
- Primary Immunodeficiency
- Other Blood Cancers
Other Countries Where Private Stem Cell Therapy Is Considered Illegal
Even in countries where legal regulations were once unclear, there are now instances where the provision of stem cell therapy is explicitly deemed illegal. In these nations, unlicensed medical facilities and companies may attempt to offer stem cell therapies, and it is crucial to ensure proper legal oversight.
Additionally, cases have been reported where some businesses and clinics in Japan advertised stem cell therapies abroad, unaware that such practices were illegal. To receive appropriate treatment, it is crucial to thoroughly investigate the latest legal regulations of the provider country.
Korea
In South Korea, stem cell cultivation is prohibited outside of certified pharmaceutical companies.
Therefore, concerns exist that illegally sourced stem cells may be circulating in the international market, requiring vigilance. Additionally, there are reports of unauthorized treatments being administered to foreign nationals.
In Korea, the cultivation and production of stem cells are regulated by the Ministry of Food and Drug Safety (MFDS), and only licensed pharmaceutical companies and designated medical facilities are authorized to perform these activities. Unauthorized cultivation or sale of stem cells is considered a violation of the Pharmaceutical Affairs Act, and offenders may be subject to penalties.
Taiwan
In Taiwan, the Regenerative Medicine Act and the Regulations on Regenerative Medicine Products were adopted in 2024, establishing a clear legal framework.
- Implementation in medical facilities is very important.Stem cell therapy is only permitted to be provided in medical facilities that have the appropriate certification.
- Persetujuan pemerintah dan kewajiban pendaftaran:Approval from the Department of Health and Welfare is required, and further registration with local jurisdictional authorities is required.
- Stem cell therapy product quality standards:Regenerative care products are classified as medicines, and manufacturing in GMP-compliant facilities is required. When manufactured or imported by a drug manufacturer, an application for inspection and registration with the Department of Health and Welfare is required.
In Taiwan, the "Regenerative Medicine Act" and the "Regulations on Regenerative Medicine Products" were enacted in June 2024. Under these laws, the provision of stem cell therapy is restricted to government-approved medical facilities, and its provision in non-medical facilities is deemed illegal. To administer stem cell therapy, approval from the Ministry of Health and Welfare and subsequent registration with local jurisdictional authorities are mandatory.
Regenerative products are classified as pharmaceuticals, and their manufacture in GMP-compliant facilities is mandatory. Upon manufacture or import, applications for inspection and registration with the Department of Health and Welfare are imperative, and violations may be subject to sanctions.
Indonesia
The Indonesian government is currently developing standards to ensure the safety of stem cell therapy.
- Stem cell therapy provider facilitiesCurrently, only state teaching hospitals can perform stem cell therapy, and private stem cell therapy is considered illegal.
- Special actionA medical economic zone has been established in the Sanur district in Bali, and there is a possibility that stem cell technology from abroad will be introduced under certain conditions.
In Indonesia, the provision of stem cell therapy is restricted by law and regulation exclusively to state-designated teaching hospitals. Pursuant to Ministry of Health Regulation No. 32, enacted in 2014, medical facilities authorized to provide stem cell therapy are limited to state-designated hospitals, and its provision in general private clinics is deemed illegal.
In addition, a medical economic zone has been established in the Sanur district of Bali, with the potential for foreign stem cell technology to be introduced under specific conditions.
Filipina
The Philippine government has introduced stringent regulations to ensure the safety of stem cell therapy.
- Only stem cell clinics integrated into large hospitals are permitted:Facilities that perform stem cell therapy are limited to medical facilities that have passed strict examinations.
- Health damage from illegal treatment:A death has been reported from treatment at an illegal private clinic, and the government urges the public to be careful.
The Philippine government issued Administrative Order AO 2013-0012 in 2013, restricting the provision of stem cell therapy solely to government-accredited facilities. To administer stem cell therapy, such facilities must be medical facilities recognized by the Philippine Department of Health (DOH), and its provision in other clinics is deemed illegal.
Reports of adverse health effects from illegal stem cell therapies have surfaced, and notably, in 2019, patient fatalities linked to uncertified treatments were confirmed. The Philippine government enforces strict regulations against unauthorized treatments, and violators may face sanctions.
Vietnam
Despite the absence of a fully established legal framework for stem cell therapy in Vietnam, a statement has been issued declaring it illegal, with the exception of specific clinical trials and research.
- In the case of clinical trials/research:It is required to pass review, evaluation, and approval from the National Biomedical Research Ethics Committee.
- Unlicensed stem cell treatment is prohibited:The provision of commercial stem cell therapy is not permitted at this time.
Although a comprehensive legal framework for stem cell therapy in Vietnam has not yet been fully established, the provision of commercial stem cell therapy without the approval of the National Biomedical Research Ethics Committee is prohibited.
Currently, stem cell therapy is recognized solely as 'clinical research,' and its unauthorized provision may constitute a violation of the Medical Act. In 2023, clinics operating without authorization for stem cell therapy were apprehended, and the government is tightening regulations.
In this manner, numerous countries have enacted stringent legal and regulatory frameworks and safety systems for stem cell therapy to safeguard public health.
On the other hand, there are entrepreneurs in Japan providing stem cell therapy that is unapproved by any country, sourcing it from abroad. However, in many countries, such practices are deemed illegal, and careful deliberation is necessary.
To Safely Receive Stem Cell Therapy Overseas - Malaysia
Currently, in Asia, only Japan and Malaysia permit the safe provision of stem cell therapy.
While autologous stem cell therapy is mainstream in Japan, for individuals seeking treatment with young and healthy Wharton's Jelly stem cells, Malaysia presents an excellent option.
Despite the absence of specific legislation governing stem cell therapy, regulations concerning safety and treatment guidelines are in place. Under government supervision, treatment can be received in an environment where both safety and quality are assured.
Handbook of Stem Cell and Cell-Based Research and Therapy (3rd Edition)
Furthermore, the provision of stem cell therapy by unlicensed medical facilities may violate the Private Healthcare Facilities and Services Act 1998 (PHFS Act 1998) and be subject to regulation by supervisory authorities, thereby ensuring that treatment can be received in an environment where safety and quality are guaranteed under government oversight.
In Malaysia, the regulation of stem cell therapy is governed by the "Guidelines for Stem Cell and Cell-Based Research and Therapy," established in 2009. Stem cell therapy can only be performed in licensed medical facilities. The use of human embryonic stem cells is prohibited, and treatments involving mesenchymal stem cells (MSCs) are carefully managed as clinical research.
To conduct stem cell therapy, approval must be obtained from the National Stem Cell Ethics Research Committee (NSCERT) under the purview of the Ministry of Health Malaysia (MOH). Furthermore, the quality management of stem cell therapy products is managed by the National Pharmaceutical Regulatory Agency (NPRA), and compliance with Good Manufacturing Practice (GMP) standards is mandatory.
In Malaysia, the use of hematopoietic stem cells and umbilical cord-derived stem cells (including Wharton's Jelly stem cells) is recognized, and facilities providing stem cell therapy must obtain approval from the Ministry of Health (MOH) and the National Stem Cell Research Ethics Sub-Committee (NSCERT). The provision of stem cell therapy by medical facilities without authorization may violate the Private Healthcare Facilities and Services Act 1998 (PHFS Act 1998) and be subject to regulation by supervisory authorities.